Related Experiment Video
Updated: Jun 13, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Targeting Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma: Rationale, Current Evidence, and a CEACAM6
Marcin Piejko1,2, Karolina Bak2, Joanna Wierciak2
13rd Department of General Surgery, Jagiellonian University Medical College, 31-202 Krakow, Poland.
Cancers
|June 12, 2026
Summary
Targeting circulating tumor cells (CTCs) shows promise for intercepting minimal residual disease (MRD) in pancreatic cancer. A CEACAM6-directed CAR-T cell therapy is proposed to improve outcomes after surgery.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Diagnostics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has high rates of post-surgical relapse and metastasis.
- Circulating tumor cell (CTC) levels correlate with early treatment failure, highlighting the need for interception strategies.
Purpose of the Study:
- To review evidence on PDAC staging, therapy, CTC detection, and ctDNA-based MRD.
- To evaluate the rationale for CEACAM6-targeted CAR-T cell therapy for PDAC.
Main Methods:
- Synthesized contemporary evidence on PDAC diagnostics and therapeutics.
- Reviewed CTC detection methods (portal vs. peripheral sampling).
- Assessed circulating tumor DNA (ctDNA) for minimal residual disease (MRD) monitoring.
Main Results:
- Higher CTC yields and stronger relapse associations found with portal sampling.
- ctDNA positivity predicts shorter disease-free survival.
- CEACAM6 overexpression in PDAC supports its potential as a therapeutic target, but challenges remain.
Conclusions:
- CTC targeting is feasible in PDAC for MRD interception.
- A CEACAM6-directed CAR-T cell therapy is proposed.
- Further trials are needed to validate this approach using composite MRD endpoints.
